Examining Medical Product Manufacturer Communications

posted by AHIP

on July 11, 2017

AHIP’s comments on two draft bills addressing pharmaceutical manufacturer communications on medical products: the “Medical Product Communications Act” and the “Pharmaceutical Information Exchange Act.” Proposed changes to the rules surrounding these communications could have far-reaching implications for the decisions made by health care providers, in consultation with their patients, about which medications and other medical products are safe, effective, and appropriate for treating their patients. We believe it is critically important for Congress to fully consider the potential impact of these proposed changes on patient safety, health outcomes, and our shared goal of promoting high quality, affordable health care for all Americans.